Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 225

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 225
---
 GH001 and GH002 and of the medical devices required to deliver these product candidates, such as 
 our proprietary aerosol delivery device for GH001;                                                                                                                                                                                   |

| • | initiate and continue research and development, including technical, nonclinical, clinical, and discovery efforts for any future product candidates; |

| • | seek to identify additional product candidates; |

| • | seek regulatory approvals for our product candidates GH001 and GH002 including the medical devices required to deliver these product candidates, such as our proprietary aerosol delivery device for GH001, or any other product 
 candidates that successfully complete clinical development;                                                                                                                                                                      |

| • | progress any nonclinical programs and any other work that may be required to lift the clinical hold n the study we proposed in our IND for GH001; |

| • | add operational, financial and management information systems and personnel, including personnel to support our product candidate and device development and help us comply with our obligations as a public company; |

| • | hire and retain additional personnel, such as clinical, quality control, scientific, commercial, sales, marketing and administrative personnel; |

| • | continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims; |

| • | establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to commercialize various products for which we may obtain regulatory approval; |

| • | comply with ongoing regulatory requirements for products approved for commercial sale, if ever; |

136 Table of Contents

| • | acquire or in-license other product candidates, medical devices to deliver our product candidates, and other technologies; and |

| • | incur increased costs as a result of operating as a public company. |

As of December 31, 2024, we had cash, cash equivalents, other financial assets and marketable securities of $182.6 million, compared to cash, cash equivalents, other financial assts and marketable securities of $222.7 million as of December 31, 2023. We believe that our existing cash, cash equivalents, other financial assets and marketable securities will be sufficient for us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with product development, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and